Search Results - Sarah Fitzsimmons

754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small c... by Haven Garber, Saranya Chumsri, Yazan Migdady, Chul Kim, Erika Hamilton, Jennifer Specht, Babar Bashir, Hirva Mamdani, Heidi Gillenwater, Yeonhee Kim, David R Spigel, Usama Gergis, Hemant S Murthy, Lubna N Chaudhary, Sarah Fitzsimmons, Bishwa J Ganguly, Hajime Hiraragi, Helle Jensen, Mary C Lessig